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IT was reported in 1964 that rats which received repeated subcutaneous injec-
tions of cadmium-precipitated ferritin developed sarcomas at the site of injection,
interstitial cell (Leydig cell) tumours ofthe testes and testicular atrophy (Haddow,
Roe, Dukes and Mitchley, 1964; Roe, Dukes, Cameron, Pugh and Mitchley, 1964).
Previous and parallel observations demonstrated that simple inorganic cadmium
salts were carcinogenic-both at the site of injection (Kazantzis, 1963; Haddow et
al., 1964) and in the testis (Parizek and Zahor, 1956; Meek, 1959; Kar and Das,
1960; Gunn, Gould and Anderson, 1963)-and it thus seemed likely that some or
all of the effects of cadmium-precipitated ferritin were due to its content of
cadmium. To confirm this hypothesis, cadmium-free ferritin was tested for
carcinogenic activity in rats and mice.
MATERIALS AND METHODS
Experiments were carried out on 48 male CB Wistar rats and on 64 male CB
stock mice. The rats, which were 6 weeks old at the beginning ofthe experiment,
were divided into test and control groups, each consisting of 24 animals. The
mice, 11 weeks old, were divided into a test group of 24 animals and an untreated
control group of 40 animals. The rats and mice were housed in metal cages and
maintained on cubed Diet No. 86 (Messrs. Dixon, Ltd., Ware, Herts.) and water ad
libitum.
Cadmium-free ferritin, prepared from horse spleen by the method of Granick
(1942), was obtained from Pentex Laboratory Reagents, Inc. (Kankakee, Illinois.
60901, U.S.A.). It was supplied as an aqueous solution containing 21 mg./ml.
and the experiments were carried out on Batch No. 10.
The dose and method of administration of cadmium-free ferritin and the
duration of treatment are shown in Table I.
TABLE I. Administration of Cadmium-free Ferritin to Rats and Mice
Total amount of
Number of Dose of cadmium- Route of Number of cadmium-free ferritin
animals free ferritin Administration injections injected (mg.)
Rats
24 0 ml. . s.c.* . 12 126
( 10 -5 mg. ferritin) (R. flank)
24 untreated controls
Mice
24 . 0-05 ml. . s.c.* 12 . 63
( 5 25 mg. ferritin) (R. flank)
40 . untreated controls -
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Animals were examined daily and sick individuals were killed at once. The
survivors were killed at approximately 21 months (rats) or 18 months (mice) after
the start of the experiment. Full post-mortem examinations were carried out
and all tissues showing macroscopic abnormalities were fixed in Bouin's solution.
Paraffin sections were prepared at 5jt and stained with haematoxylin and eosin.
RESULTS
Effects of cadmium-free ferritin in rats
Survival ofrats treated with cadmiun-free ferritin was poorer than that ofthe
controls. Within 12 months of the start of the experiment, 9 animals had died
or were killed because they were sick. Only 2 survived for more than 18 months
and these were kiLled when the experiment was terminated at 21 months. Ofthe
control rats, 17 were alive at 12 months and 11 at 18 months. Several factors
contributed to the earlier deaths of the ferritin-treated animals. Fourteen of the
treated rats developed severe chronic nephritis as compared with only 5 of the
controls; in one ofthe 14 there was a renal abscess and another had vesical calculi.
Chronic hepatitis with fatty degeneration or centrilobular necrosis was seen in 5
of the treated rats as compared with 2 controls; in 2 of the 5 (but in neither ofthe
controls) bile duct proliferation was also noted.
Brown discoloration of the subcutaneous tissues was regularly observed at the
site ofinjection in the treated rats. Iron-laden macrophages accumulated in large
numbers but there was little proliferation offibrous tissue and in only 1 rat, killed
after 16 months, was there marked fibrosis. No injection-site tumours were seen.
One rat from the test group developed a lymphomatous mass in the right lung and,
in another test animal, a mammary fibroadenoma was found. The testes were
normal in all animals, with well-preserved seminiferous tubules and no proliferation
of interstitial cells.
One neoplasm was observed among the 24 untreated control rats-a pleomor-
phic sarcoma arising from the periosteum ofthe femur. The testes were normal in
all animals.
Effects ofcadmium-freeferritin in mice
In contrast to the finding in rats, survival in the test and control groups ofmice
was similar. Ofthe 24 test animals, 16 were alive at 12 months and 7 at 18 months
when the experiment was terminated. Among the 40 control mice, 30 were alive
at 12 months and 11 at 18 months. The spectrum and incidence ofnon-neoplastic
diseases-particularly hepatic degeneration, amyloidosis and cystic nephritis-
were similar in the 2 groups.
The changes at the injection sites in response to ferritin consisted of brown-
staining of the subcutaneous tissues and infiltration by siderophages. Slight
fibrosis was seen in 3 mice and epidermal ulceration developed in 1 animal. No
local neoplasms were seen. Distant neoplasms encountered were malignant
lymphomas (5 mice), pulmonary adenomas (5 mice) and hepatomas (2 mice). The
testes were normal in all the test animals.
A similar distribution of tumours was seen in the 40 untreated control mice-
malignant lymphomas (11 mice), pulmonary adenomas (6 mice), hepatomas (4
mice). In addition, one animal developed a squamous papilloma of the skin.
The testes were consistently normal.NON-CARCINOGENICITY OF CADMIUM-FREE FERRITIN
DISCUSSION
The total dose of cadmium-free ferritin given to the rats in the present investi-
gation (126 mg.) was more than double that of cadmium-precipitated ferritin (56
mg.) used in the previous studies by Haddow and his colleagues (Haddow et al.,
1964; Roe et al., 1964). But despite the use of this larger dose, no sarcomas
appeared at the site of injection and the testes remained normal. It thus seems
likely that it was the cadmium in the cadmium-precipitated ferritin which was
responsible for the lesions previously observed. The failure to induce local
sarcomas must, however, be interpreted with caution because the survival ofmany
ofthe rats in the test group was short in relation to the induction-time of sarcomas
produced in the earlier experiments with cadmium-precipitated ferritin. Haddow
et al. (1964), observed the first injection-site sarcoma at 14 months and the average
time of appearance of the 7 sarcomas which subsequently developed was over 21
months. On the other hand, the cadmium-free ferritin produced significant
fibrosis at the injection-site in only 1 animal; whereas in the earlier experiments,
intense proliferation of fibrous tissue was seen in all the test animals, and was
palpable in them long before they developed local sarcomas.
The failure to induce neoplasms with cadmium-free ferritin in mice cannot be
attributed to poor survival though it may be due either to insufficient dosage or to
insensitivity of mice to the induction of cancer by this agent. In the previous
experiments with cadmium-precipitated ferritin, no tumours arose in response to
a total dose of 21 mg. ferritin: in the present study, a dose of63 mg. cadmium-free
ferritin was similarly without effect.
The experiments are not entirely conclusive. Nevertheless they show that
cadmium-free ferritin is unlikely to be more than very weakly carcinogenic and
that it does not cause non-neoplastic degenerative changes in the testicular tubules.
In this connection itmayberelevantthatcadmium-precipitated ferritinismarkedly
toxic to cells in tissue culture but cadmium-free ferritin is entirely without effect
(Eybl and Ryser, 1964).
The findings are of some general relevance, especially to the study of the
mechanism of carcinogenesis by asbestos and by various iron compounds. Asbes-
tos bodies consist of asbestos fibres coated with material which contains ferritin
(Davies, 1965). The present results suggest that this deposit offerritin is oflittle
importance in relation to the induction of neoplasms by asbestos fibres (Wagner,
1962; Roe, Carter, Walters and Harington, 1967) Muir and Golberg (1961) have
shown that after two introductions of iron dextran into the subcutaneous tissues,
the iron moiety is stored either as ferritin or as haemsoderin. Despite this
conversion, sarcomas frequently arise at the site ofinjection ofiron-dextran in rats
and in various other species (see Roe, 1967, for review). In the first ofthe present
experiments, the total amount of iron injected in the form offerritin (126 mg. per
rat) was less than the total amount (300 mg.) of iron in the form of iron dextran
required to induce injection-site sarcomas in 25 % of rats of the same strain (Roe,
1967). The non-carcinogenicity offerritin in amounts likely to be formed after the
injection of relatively large doses of iron dextran has, therefore, yet to be
established.
SUMMARY
Twenty-four male CB Wistar rats were given 12 once-weekly subcutaneous
injections of 10-5 mg. cadmium-free ferritin in 0-1 ml. water. One rat developed
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marked fibrosis at the site of injection but none developed local tumours. No
neoplasms ofother sites attributable to treatment were encountered and the testes
of all rats were macroscopically and histologically normal.
Twenty-four male CB stock mice received 12 once-weekly subcutaneous
injections of 5-25 mg. cadmium-free ferritin. No local tumours or testicular
changes were seen and the incidence and spectrum ofneoplasms at other sites were
similar to those in a group of 40 comparable control mice.
These negative findings are discussed in relation to carcinogenesis by iron-
dextran and asbestos.
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